<DOC>
	<DOCNO>NCT00107172</DOCNO>
	<brief_summary>This randomized phase III trial study surgery internal radiation therapy see well work compare surgery alone treat patient stage I non-small cell lung cancer . Surgery may effective treatment non-small cell lung cancer . Internal radiation use radioactive material place directly near tumor kill tumor cell . It yet know whether surgery internal radiation therapy effective surgery alone treat non-small cell lung cancer .</brief_summary>
	<brief_title>Surgery With Without Internal Radiation Therapy Treating Patients With Stage I Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To ascertain whether patient treat sublobar resection ( SR ) + brachytherhapy ( BX ) long time local recurrence compare patient treat SR ( local recurrence include recurrence within lobe hilum [ N1 node ] , progression staple line treatment effect scar subside ) . SECONDARY OBJECTIVES : I . To compare procedure specific morbidity mortality study arm . II . To compare overall survival failure-free survival study arm . III . To assess freedom regional distant recurrence . IV . To assess effect histological cytologic positive resection margin time local recurrence . V. To determine effect brachytherapy quality life ( QoL ) . VI . To determine effect brachytherapy pulmonary function . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients undergo open thoracoscopic sublobar resection comprise either wedge resection anatomical segmentectomy . ARM II : Patients undergo surgery arm I . Patients also undergo intraoperative brachytherapy comprise iodine I 125 implant resection margin . After completion study treatment , patient follow 3 , 6 , 12 , 18 , 24 , 30 , 36 month yearly 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>PART I : PREOPERATIVE CRITERIA ( PREREGISTRATION/RANDOMIZATION ) Patients must suspicious lung nodule clinical stage I nonsmall cell lung cancer ( NSCLC ) Patient must mass = &lt; 3 cm maximum diameter compute tomography ( CT ) size estimate : clinical stage Ia select Ib ( i.e. , visceral pleural involvement ) Patient must CT scan chest upper abdomen within 60 day prior date preregistration Eastern Cooperative Oncology Group ( ECOG ) /Zubrod performance status 0 , 1 , 2 Patient must meet least one major criterion meet minimum two minor criterion describe : Major criterion Forced expiratory volume 1 second ( FEV1 ) = &lt; 50 % predict Diffusing capacity lung carbon monoxide ( DLCO ) = &lt; 50 % predict Minor criterion Age &gt; = 75 FEV1 5160 % predict DLCO 5160 % predict Pulmonary hypertension ( define pulmonary artery systolic pressure great 40 mmHg ) estimate echocardiography right heart catheterization Poor leave ventricular function ( define ejection fraction 40 % less ) Resting exercise partial pressure oxygen ( pO2 ) = &lt; 55 mm Hg peripheral capillary oxygen saturation ( SpO2 ) = &lt; 88 % Partial pressure carbon dioxide ( pCO2 ) &gt; 45 mm Hg Modified Medical Research Council ( MMRC ) Dyspnea Scale &gt; = 3 Patient must previous intrathoracic radiation therapy Women childbearing potential must negative serum urine pregnancy test No prior invasive malignancy , unless diseasefree &gt; = 5 year prior preregistration ( exception : nonmelanoma skin cancer , insitu cancer ) PART II : INTRAOPERATIVE CRITERIA ( REGISTRATION ) Patient must biopsyproven NSCLC Patient must suspicious mediastinal lymph node ( &gt; 1 cm shortaxis dimension CT scan positive positron emission tomography [ PET ] scan ) assess one follow method confirm negative involvement NSCLC ( mediastinoscopy , endoesophageal ultrasound guide needle aspiration , CTguided , videoassisted thoracoscopic open lymph node biopsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
</DOC>